Trump said that individuals or companies that invest more than $1 billion in the United States will get accelerated approval. US President-elect Trump wrote in a post on his social media Truth Social on Tuesday: "Any individual or company that invests more than $1 billion in the United States will get comprehensive and accelerated approval and permission, including but not limited to all environmental approvals." This is the latest sign that Trump intends to relax the supervision of federal agencies and attract more foreign investment during his second term.The new Indian central bank governor: We have made progress in inclusive finance, but there is still more work to be done; Efforts will be made to further utilize technology without stifling innovation.Ukraine said that the death toll from Russian attack on Zaporoge rose to seven. Ivan Fedoroff, head of military and political affairs in Zaporoge, Ukraine, said on the 11th that the Russian attack on Zaporoge on the 10th had caused seven deaths. (CCTV News)
Kazakhstan said that Russia's Druzhba oil pipeline was not damaged by Ukraine's overnight strike.Qujiang Wenlv: It received a warning letter from Shaanxi Supervision Bureau, and Qujiang Wenlv announced that the company received the Decision on Taking Measures to Issue Warning Letters to Xi 'an Qujiang Cultural Tourism Co., Ltd., Xie Xiaoning and Xi 'an Qujiang Tourism Investment Co., Ltd. issued by Shaanxi Supervision Bureau of China Securities Regulatory Commission on December 10, 2024. After investigation, the company delayed the disclosure of the major event that 8.23% of the company's shares held by the controlling shareholder Xi 'an Qujiang Tourism Investment Co., Ltd. were to be disposed of by the judiciary, which violated the relevant provisions of the Measures for the Administration of Information Disclosure of Listed Companies. According to Article 52 of the Measures, Shaanxi Supervision Bureau decided to take administrative supervision measures to issue warning letters to the company, Xie Xiaoning, the relevant responsible person, and Qujiang Travel Investment, the controlling shareholder. The company will seriously rectify, strengthen information disclosure and corporate governance, and improve the operation level and information disclosure quality.Sarah Friar, CFO of OpenAI: Corporate customers will pay (at least) thousands of dollars for using artificial intelligence (AI) tools. In the end, it will be reasonable.
Thirteen people lost contact due to the road collapse in Shenzhen, Guangdong Province. According to the website of the Emergency Management Department on December 11, the the State Council Work Safety Committee issued the Notice on Handling Major Production Safety Accidents on December 10. On December 4, 2024, a major road collapse accident occurred at the construction site of No.5 bid section of Shenjiang Railway in Hangcheng Street, Baoan District, Shenzhen, which has caused 13 people to lose contact. According to the Measures for Handling Major Accidents, the the State Council Safety Committee decided to supervise the handling of this major accident. Guangdong Province should, in accordance with the Regulations on the Reporting, Investigation and Handling of Production Safety Accidents and other relevant laws, regulations and rules, promptly organize accident investigations, quickly identify the cause of accidents, and study and put forward handling opinions in strict accordance with the requirements of accident investigations. Before the accident is closed, the accident investigation report (not finalized) shall be submitted to the the State Council Safety Committee Office for examination and approval, and Guangdong Province shall be responsible for approving the case and announcing it to the public. After the case is closed, the accident investigation report and the implementation of the accident handling decision shall be reported to the the State Council Safety Committee Office for the record.Market information: Nissan will appoint JÉRÉMIE PAPIN as the chief financial officer on Wednesday.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.